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About this report
This report presents the key activities performed by the EMCDDA and Europol in 2014, 
with details on all the relevant activities in support of the implementation of Council 
Decision 2005/387/JHA on the information exchange, risk assessment and control 
of new psychoactive substances, including new psychoactive substances notified in 
2014, Joint Reports produced, risk assessments conducted and public health alerts 
and advisories issued.
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-
assessment and control of new psychoactive substances, OJ L 127, 20.5.2005, p. 32.
Available at:
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32005D0387:EN:HTML
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I Background to this report
As part of the response to new psychoactive substances within the European Union (EU), 
the Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk 
assessment and control of new psychoactive substances (hereafter the ‘Council Decision’) 
established a mechanism for rapid information exchange on substances that may pose 
public health and social threats, including the involvement of organised crime. This 
provides a legal basis for the institutions of the EU and the Member States to monitor all 
new narcotic and psychotropic substances that appear on the European drug scene. 
Where necessary, the Council Decision also provides for an assessment of the risks 
associated with these new substances, so that control measures deriving from Member 
States’ obligations to the United Nations drug control conventions (1) can also be applied 
to new psychoactive substances.
Under Article 4 of the Council Decision, the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) and Europol, in close collaboration with their respective expert 
networks, the Reitox National Focal Points and Europol National Units, are assigned a 
central role in detecting, notifying and monitoring new psychoactive substances. The 
information exchange element of the Council Decision has been implemented by the 
EMCDDA and Europol as the European Union Early Warning System on New Psychoactive 
Substances (hereafter ‘EU Early Warning System’). In addition, where necessary, and in 
cooperation with the European Medicines Agency (EMA), the EMCDDA and Europol may 
collect, analyse and present information on a new psychoactive substance in the form of a 
Joint Report (Article 5). This report provides evidence to the Council of the European Union 
and the European Commission on the need to request a risk assessment on a new 
psychoactive substance. Such a risk assessment examines the health and social risks 
posed by a new substance including: the use of, manufacture of and traffic in a new 
psychoactive substance; the involvement of organised crime; and the possible 
consequences of control measures. In order to conduct the risk assessment, the EMCDDA 
convenes a special meeting under the auspices of its Scientific Committee, extended with 
additional experts as necessary (Article 6).
To ensure transparency in the implementation of the Council Decision, Article 10 
stipulates that: 
‘The EMCDDA and Europol shall report annually to the European Parliament, the Council 
and the Commission on the implementation of this Decision. The report will take into 
account all aspects required for an assessment of the efficacy and achievements of the 
system created by this Decision. The report shall, in particular, include experience relating 
to coordination between the system set out in this Decision and the Pharmacovigilance 
system.’
In compliance with Article 10, the EMCDDA and Europol herewith present the tenth such 
annual report which covers the period 1 January to 31 December 2014. The report outlines 
the results of the implementation, describes key issues arising from accumulated 
experiences and serves as a monitoring tool. The reader is referred to the text of the 
Council Decision, to facilitate the reading of this report (2). Annex 1 provides the list of new 
psychoactive substances notified for the first time in 2014. This includes the International 
Union of Pure and Applied Chemistry (IUPAC) chemical name, the reporting country, and 
(1)  The 1961 United Nations Single Convention on Narcotic Drugs and the 1971 United Nations Convention on 
Psychotropic Substances.
(2)  Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new 
psychoactive substances, OJ L 127, 20.5.2005, p. 32.
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date of notification for each substance. Further information on these substances is 
available from the EMCDDA and Europol. Annex 2 and 3 provide a detailed analysis of new 
psychoactive substances in Europe for 2014 from the perspective of the EU Early Warning 
System. Annex 2 and 3 are also available online and can be downloaded at: www.emcdda.
europa.eu/publications/2015/new-psychoactive-substances
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I 1. Overview
The year 2014 was particularly busy for those involved in detecting, monitoring and 
responding to new psychoactive substances across the European Union (EU). This was 
due to the continued growth in the number, type and availability of new drugs detected as 
well as the increase in the number of serious harms that were reported to the EMCDDA 
(see ‘Headline activities in 2014’). In addition, the number of law enforcement 
investigations and activities concerning new psychoactive substances has also increased. 
With this increase in substances comes an increase in the amount of information that is 
collected. The EMCDDA collects a diverse range of information on new psychoactive from 
30 countries, international partners, experts and a large amount of information on harms 
from its monitoring of open source information. Overall, new psychoactive substances 
continued to be a high policy priority in the EU and in the Member States.  
n  101 new psychoactive substances were formally notified for the first time in 
2014. This compares to 81 in 2013, 74 in 2012, 48 in 2011 and 41 in 2010.
n  The first formal EU law enforcement Joint Investigation Team was established 
entirely focussed on an Organised Crime Group responsible for bringing new 
psychoactive substances from China to a Member State for distribution across 
the EU.
n  16 public health alerts were issued by the EMCDDA.
n  6 risk assessments were conducted by the Scientific Committee of the EMCDDA:
I  25I-NBOMe, a substituted phenethylamine with hallucinogenic effects that was 
sold as a ‘legal’ replacement to LSD;
I  AH-7921, a synthetic opioid;
I  MDPV, a synthetic cathinone derivative closely related to pyrovalerone;
I  Methoxetamine, an arylcyclohexylamine that was sold as a ‘legal’ replacement 
to ketamine;
I  4,4′-DMAR, a psychostimulant structurally related to the internationally 
controlled drugs 4-methylaminorex (4-MAR) and aminorex; and,
I  MT-45, a synthetic opioid with analgesic potency similar to morphine.
Headline activities in 2014
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I 2.  Implementation arrangements and cooperation with the European Union Pharmacovigilance system
I 2.1. Specific implementation arrangements
2.1.1. Assistance to national early warning systems 
In 2014 the EMCDDA and Europol continued to provide technical expertise and support to 
the national early warning systems within the Reitox National Focal Points and Europol 
National Units in order to assist them in their work on new psychoactive substances. 
Technical expertise and support was also provided to the Member States, the European 
Parliament, the Council of the European Union, the European Commission, as well as EU 
agencies. 
The analytical data available to the EU Early Warning System Network continued to be 
expanded during 2014. In addition, data and information was routinely provided on an 
informal basis by international partners, including Australia, the United States and Japan. 
This is an important aspect of the exchange of information and emphasises the global 
nature of the phenomenon. 
The EMCDDA also expanded its collection of information related to new psychoactive 
substances from open source information which was made available to the Member 
States on the European Database on New Drugs (EDND). 
2.1.2. Annual meeting of the EU Early Warning System Network 
The 14th Annual meeting of the Reitox Early Warning System Network took place in June 
2014. The meeting was organised in conjunction with the second Spice II Plus – EMCDDA 
conference. Topics discussed at the annual EWS meeting included:
n  results of implementation of Council Decision 2005/387/JHA, including EMCDDA-
Europol Joint Reports and Risk Assessments launched in 2014;
n  development of a framework for the toxicovigilance of new psychoactive substances 
and strengthening the identification and reporting of serious adverse events; 
n  revision of reporting tools.
2.1.3. Supporting activities
During 2014 the EMCDDA and Europol continued to be prominently involved in organising 
events and participating in activities that are designed to develop the EU Early Warning 
System Network and provide support to others working in the field of new psychoactive 
substances. These events and activities provide a platform to improve collaboration 
among partners and promote best practice in order to strengthen early warning activities. 
n  In May, the EMCDDA co-organised the Third International Conference on Novel 
Psychoactive Substances took place in Rome, Italy. 
n  Also in May, the EMCDDA participated and delivered training in the Europol – CEPOL 
training course on dismantling illicit drug laboratories. The course was held in the 
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International Training Centre for Combating Clandestine Laboratories (ITCCCL) in 
Legionowo, Poland. The training was attended by 32 law enforcement and forensic 
experts from 18 Member States, Colombia and a representative from Eurojust.
n  In September, the EMCDDA and Europol co-organised the 3rd Law enforcement expert 
meeting on new psychoactive substances, which was held at Europol. The meeting was 
focused on the exchange of best practice and experience concerning investigations on 
new psychoactive substances, including the sale of new psychoactive substances via 
the so-called Internet ‘dark sites’.
The EMCDDA also organised or participated in a number of scientific conferences and 
meetings with dedicated sessions on new psychoactive substances, reflecting the 
relevance of this area for traditional illicit drug areas and established key epidemiological 
indicators. This included meetings covering general population surveys, drug-related 
deaths and problem drug use. 
2.1.4. Europol
Europol has observed that law enforcement agencies across the EU are now becoming 
more involved with new psychoactive substances investigations. The law enforcement 
response has included the use of advanced tactics such as the controlled deliveries and 
cyber-purchase operations. Also, in 2014 the first formal EU Joint Investigation Team was 
established between two Member States, Europol and Eurojust, entirely focussed on an 
Organised Crime Group involved in bringing different new psychoactive substances from 
China to the EU and their distribution across the EU. 
Strategically, new psychoactive substances are an EU priority in terms of the Policy Cycle 
for Organised Crime. The European Multidisciplinary Platform against Criminal Threats 
(EMPACT) Synthetic Drugs priority includes new psychoactive substances and several 
operational activities were conducted in the framework of the Operational Action Plan in 
2014. The EMPACT Synthetic Drugs Operational Action Plan in 2015 will see even more 
activities focussed on the issue of new psychoactive substances.
As noted in previous years, China has been reported by Member States as the main source 
of new psychoactive substances delivered to Europe. Some of the most commonly 
reported new psychoactive substances were MDPV, pentedrone, 3-MMC, alpha-PVP and 
4-fluoroamphetamine. According to Dutch authorities, 4-fluoroamphetamine was one of 
the most popular and best sold new psychoactive substances in the smart shops in the 
Netherlands in 2014 and it appears that a market has been established for this new 
psychoactive substances. To a lesser extent India also plays a role as a source country and 
it has been noted that mephedrone (4-methylmethcathinone) which was subject to control 
measures across the EU in 2010, is being imported into to the EU from India. For example, 
Germany reported a seizure of mephedrone (25 kg), which was shipped from India to 
Germany via the United Kingdom. Investigations conducted in the Member States and 
supported by Europol suggest that some Member States are emerging as European hubs 
for receiving the new psychoactive substances from source countries. New psychoactive 
substances are mainly imported in the form of bulk powder or herbal substance. 
Subsequently, they are further processed for sale to consumers. This can involve mixing 
with other substances such as caffeine, or impregnating chemicals onto herbs or pressing 
into tablets before packaging takes place. On some occasions this is done by Organised 
Crime Groups. Although rare, the chemical synthesis of new psychoactive substances has 
also been reported. Poland, for example, reported illicit laboratories making mephedrone in 
2012 and alpha-PVP in 2013. The majority of illicit sites related to new psychoactive 
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substances production in Europe are linked with processing steps only, i.e. the conversion 
of bulk materials into retail units. Slovenian authorities reported such a large scale 
operation where significant quantities of new psychoactive substances were being 
processed into ‘legal high’ products, including liquid refills containing synthetic 
cannabinoids for use in electronic cigarettes. Distribution of new psychoactive substances 
is generally well organised e.g. sale on the Internet, mail service, etc., to other Member 
States and beyond.
In 2014 only one production site was reported to Europol, which related to the seizure of a 
tableting site in June 2014 in Hungary. Bulk quantities of pentedrone and alpha-PVP were 
seized as well as the equipment and chemicals used for processing the substances into 
tablet form. Europol’s dedicated synthetic drug team supported the Hungarian 
investigation on the spot. Based on intelligence provided by Member States and a general 
assessment of new psychoactive substances market in Europe, Europol has assessed that 
more production facilities are operating in the EU.
Another related issue of concern is the importation of precursors that can be used for the 
synthesis of new psychoactive substances. At the beginning of 2014, Dutch authorities 
reported a 15 kg seizure of N‐acetylmephedrone which is a starting material for 
mephedrone. The consignment, which was falsely declared as another chemical, 
originated from an import-export company registered in Hong Kong and was destined for a 
business registered in the Netherlands. Bearing in mind the lack of awareness of 
precursors for new psychoactive substances by law enforcement and their non-controlled 
status, Europol has assessed that criminal groups could exploit this gap in future and the 
synthesis of some new psychoactive substances in Europe may become more common.  
Also during 2014, Romania and Latvia reported that new legislation adopted in their 
countries had changed the distribution of new psychoactive substances from the smart 
shops to either public or hidden websites hosted abroad (United States, United Kingdom). 
The distribution is typically made via courier transportation companies and the profits 
gained via this activity are reported to be substantial. 
Many countries are taking concerted law enforcement actions targeting the supply of new 
psychoactive substances. In August 2014, for example, Europol specialists were in 
Scotland, United Kingdom to support a national multi-agency operation targeting premises 
suspected of selling new psychoactive substances. The operation was preceded by a 
two-week nationwide marketing campaign to raise awareness of the dangers of taking new 
psychoactive substances.
I 2.2.  Cooperation with the European Medicines Agency and the Pharmacovigilance system
During 2014 the European Medicines Agency (EMA) and the EMCDDA continued to 
regularly exchange information on new psychoactive substances according to their 
respective obligations under the Council Decision and EU pharmacovigilance legislation 
and the working arrangement between the two agencies (3).
(3)  Working arrangement between the European Medicines Agency (EMA) and the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA), signed on 7 September 2012. Available at: www.emcdda.europa.eu/
attachements.cfm/att_185319_EN_EMA-EMCDDA-2012workingarrangement.pdf 
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This included formal consultations and exchange of information took place in order to 
prepare the Joint Reports on 4,4′-DMAR and MT-45 (under the scope of Article 5, see 
section 3.3)., as well as ad hoc reports relating to the misuse and abuse of medicinal 
products and/or active pharmaceutical ingredients used therein that had been notified as 
new psychoactive substances. 
Diverted or unauthorised imported medicinal products have become a group of new 
psychoactive substances of increasing importance, which is reflected in the growing 
number of medicines monitored by the EU Early Warning System. Four of the new 
substances notified in 2014 are used as active pharmaceutical ingredients in medicines 
authorised within the European Union: bupropion, orphenadrine, quetiapine and tramadol. 
At the request of the EMA , the EMCDDA undertook a data collection exercise with the 
Early Warning System Network to provide the information on quetiapine and bupropion 
abuse, misuse (4) and dependency at the national level.
(4)  Note the terms ‘misuse’ and ‘abuse’ are used in their regulatory sense. See: www.ema.europa.eu/docs/en_GB/
document_library/Other/2013/05/WC500143294.pdf 
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I 3. Core activities
I 3.1. Early warning (Article 4)
3.1.1. New psychoactive substances notified in 2014
During 2014 101 new psychoactive substances were notified for the first time within the 
European Union (Figure 1, Annex 1, Annex 2 and Annex 3). This continues the year on year 
increase in the number of new substances that have been notified since 2008 and 
compares to 81 in 2013, 74 in 2012, 48 in 2011 and 41 in 2010. 
FIGURE 1
Number of new psychoactive substances notified for the first time to the EU Early 
Warning System, 2005–14 (5)
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Note: No notifications in 2014 for Aminoindanes, Arylcyclohexylamines, Piperazines, Piperidines and pyrrolidines or 
Plants and extracts
Of the 101 new psychoactive substances reported during 2014, 31 were cathinones and 
30 were synthetic cannabinoids (6). This brings the total number of synthetic cannabinoids 
reported since December 2008 to 134, making them the largest group of substances 
monitored by the EU Early Warning System; the large number clearly illustrating the 
continuing attempts by manufacturers to produce new substances in order to circumvent 
drug control measures. Also reported in 2014 were: 9 phenethylamines, 5 opioids, 
(5)  The 2011 annual implementation report listed 49 substances as notified through the EU Early Warning System in 
2011; this figure should have been 48. The benzodiazepine phenazepam (7-bromo-5-(2-chlorophenyl)-1,3-dihydro-
1,4-benzodiazepin-2-one), was notified by Germany in July 2011 but it had been previously formally notified as 
‘fenazepam’ by Finland, on the first half of 2007.
(6)  The term ‘synthetic cannabinoids’ is used here to include: synthetic cannabinoid receptor agonists (such as 
JWH-018 which is a CB1 and CB2 receptor agonist); allosteric modulators (such as Org 27569) that change the 
structure of the cannabinoid receptors leading to altered activity when a ligand binds to the receptors; and, 
substances that act as inhibitors of the fatty-acid amide hydrolase (FAAH), which catalyses the intracellular 
hydrolysis of the endocannabinoid anandamide (such as URB597).  
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5 tryptamines, 4 arylalkylamines, 4 benzodiazepines, and 13 substances that do not 
conform to the previous groups (Figure 1). Of particular concern to the EMCDDA and 
Europol in this respect is the number of potent new synthetic opioids — such as 4-fluoro-
butyrfentanyl (substance 23 in Annex 1), W-18 (substance 62), acetylfentanyl (substance 
70) and the fentanyl butanamide analogue (substance 60) — reported this year.
Technical profiles were created on the European Database on New Drugs (EDND) for each 
of the notified substances. During the course of 2014, 573 reporting forms were submitted 
by the EU Early Warning System Network which were processed, analysed and added to 
the EDND. The information from these forms, as well as from other sources, was used to 
update 392 technical profiles on the EDND. Regular searches of the scientific and medical 
literature were conducted by the EMCDDA, and additional law enforcement information 
provided by Europol helped facilitate these profile updates.
Technical expertise and assistance were provided to the Member States on a daily basis. 
Sixteen public health alerts were issued to the EU Early Warning System Network (section 
3.2). Additional data collection and analysis took place on an ad hoc basis, including for 
the Joint Reports on 4,4′-DMAR and MT-45 (section 3.3). 
3.1.2. Revision of reporting tools – 2013 seizure data 
The reporting tools for collecting and storing data on new psychoactive substances – as 
defined in the EWS operating guidelines (7) – were revised in 2014, aiding both data entry 
into the EDND as well as data analysis. In particular, Joint Report Questionnaires and EWS 
Progress and Final Reports were collected using a new Excel format. Trends analysis on 
the seizure data collected through EWS Progress and Final Reports was undertaken for 
the first time (Annex 2 and Annex 3) (see ‘Headline seizure data from 2013’).
n  46 730 seizures of new psychoactive substances amounting to more than 
3.1 tonnes;
n  21 495 seizures of synthetic cannabinoids amounting to almost 1.6 tonnes;
n  10 657 seizures of synthetic cathinones amounting to more than 1.1 tonnes;
n  Seven-fold increase in reported seizures of new psychoactive substances 
compared to 2008;
n  299 different new psychoactive substances detected across Europe, including 
many of those seen in previous years.
More information is available in Annex 2 and 3 (New psychoactive substances in 
Europe. An update from the EU Early Warning System (March 2015), also available at: 
www.emcdda.europa.eu/publications/2015/new-psychoactive-substances
Headline seizure data from 2013
(7)  EMCDDA-Europol Early-warning system on new psychoactive substances — operating guidelines, 2007. Available 
at: www.emcdda.europa.eu/html.cfm/index52448EN.html 
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I 3.2. Public health alerts
Public health alerts are a core activity of the EMCDDA that provide added value to the 
Member States (8). Alerts are issued by e-mail within the Early Warning System Network 
after detection of a signal by the EMCDDA. Usually such signals are related to deaths or 
other serious harms associated with new psychoactive substances. Information is also 
exchanged on psychoactive substances that are controlled under the United Nations drug 
conventions when new forms of use that may pose a risk to public health are detected. 
Alerts may also provide information on possible public health related measures in 
accordance with the mandate and procedures of the EMCDDA.
Sixteen public health alerts were issued to the EU Early Warning System Network during 
2014. A summary of some of these alerts is provided below.
4,4′-Dimethylaminorex (4,4′-DMAR), 6 February 2014
An alert was issued in February 2014 after the United Kingdom national focal point 
reported 18 deaths associated with the use of 4,4′-DMAR, a psychostimulant structurally 
related to the controlled drugs 4-methylaminorex (4-MAR) and aminorex. On 6 February 
2015, Europol and EMCDDA published a joint early warning notification focusing on the 
link between this substance and the fatal cases. Based on these cases and deaths 
previously reported by Hungary, the Joint Report procedure was launched on 27 February 
2014 (see section 3.3). The Joint Report was submitted to the Council, Commission and 
EMA on 8 May 2014. This led to a request from the Council for a formal risk assessment, 
which was subsequently conducted on 16 September 2014 by the extended Scientific 
Committee of the EMCDDA.
MT-45, 25 February 2014
An alert was issued in February 2014 after the Swedish national focal point reported 11 
deaths and 2 serious non-fatal intoxications associated with MT-45. After the assessment 
of available information, a data collection for the preparation of a Joint Report was 
launched on 16 April 2014 (see section 3.3). The Joint Report was submitted to the 
Council, Commission and EMA on 25 June 2014. This led to a request from the Council for 
a formal risk assessment which was conducted by the extended Scientific Committee of 
the EMCDDA on 16 September 2014.
5F-PB-22, 27 February 2014
An alert was issued in February 2014 after the EMCDDA identified reports of 5 deaths 
associated with the use of synthetic cannabinoid 5F-PB-22 in the United States.  Deaths 
occurred from July to November 2013. Although at that time the EMCDDA had not 
received any reports of adverse events associated with 5F-PB-22 in Europe, the alert was 
issued based on large seizures of 5F-PB-22 and the detection of the substance in ‘legal 
highs’ sold within the European Union.
ADB-PINACA, 4 March 2014
An alert was issued in March 2014 after the EMCDDA identified reports of an outbreak of 
non-fatal intoxications in the United States that were associated with the use of synthetic 
(8)  Alerts and advisories issued by the Early Warning System are not legally binding and Member States are not 
obliged to act upon them.
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cannabinoid ADB-PINACA. 263 cases of possible exposure were identified in less than one 
month in 2013. Although at that time the EMCDDA had not received any reports of adverse 
events associated with ADB-PINACA in Europe, the alert was issued based on the 
detection of ADB-PINACA in ‘legal highs’ sold within the EU.
2-MeO-diphenidine, 8 May 2014
An alert was issued in May 2014 after the United Kingdom national focal point reported a 
death associated with 2-MeO-diphenidine, a substance which is purported to have similar 
effects to methoxetamine.
3-MeO-PCP, 10 October 2014 
An alert was issued in October 2014 after the Swedish national focal point reported 3 
deaths associated with 3-MeO-PCP. 3-MeO-PCP is a derivative of PCP, the dissociative 
anaesthetic substance controlled under Schedule II of the 1971 UN Convention 
on Psychotropic Substances.
Diphenidine, 10 October 2014
An alert was issued in October 2014 after the Swedish national focal point reported 9 
analytically confirmed non-fatal intoxications associated with the use of diphenidine. A 
further 9 non-analytically confirmed non-fatal intoxications were noted in the report.  
‘Spice’, 14 October 2014
An alert was issued in October 2014 after the EMCDDA identified media reports of two 
outbreaks of serious adverse events in the Russian Federation associated with the 
smoking of a ‘legal designer drug’ or ‘Spice’. The substance involved was identified to be 
‘MDMB (N) BZ-F’ (MDMB-FUBINACA) which has not been detected within the European 
Union at the time of writing this report (May 2015).
Butyrfentanyl, 17 October 2014
An alert was issued in October 2014 after the Swedish national focal point reported a case 
of serious non-fatal intoxication associated with the potent opioid butyrfentanyl. The 
symptoms included respiratory depression, probably also cardiac arrest. Butyrfentanyl is a 
homologue of the potent opioid analgesic fentanyl.
α-PVT, 21 October 2014
An alert was issued in October 2014 after the Swedish national focal point reported a 
death associated with α-PVT which occurred in 2014. α-PVT is a derivative of the 
cathinone α-PVP and is believed to have stimulant-type effects. 
4F-α-PVP, 23 October 2014 
An alert was issued in October 2014 after the Swedish national focal point reported 2 
deaths associated with the 4F-α-PVP.  4F-α-PVP is a synthetic cathinone which is believed 
to have stimulant-type effects.
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Cocaine believed to be white heroin, 28 November 2014
An alert was issued in November 2014 after the Public Health Service in Amsterdam 
issued an alert regarding 3 deaths and several serious non-fatal intoxications linked to 
cocaine that had been purchased from the street. At that time it was reported that the 
substance involved was believed to be white heroin.
MDMB-CHMICA, 12 December and 19 December 2014
Two alerts related to the MDMB-CHMICA were issued in December 2014. The first alert 
was issued after the Austrian national focal point reported 7 non-fatal intoxications 
associated with the use of a ‘herbal mixture’ product called ‘Bonzai citrus’ and/or ‘Bonzai 
Winter Boost’ which was thought to contain MDMB-CHMICA. The second alert was issued 
after the Swedish national focal point reported 4 deaths and 6 non-fatal intoxications 
associated with the use of MDMB-CHMICA that occurred between September and 
November 2014.
PMMA, 22 December 2014
An alert was issued in December 2014 after the Dutch Drugs Information and Monitoring 
System (DIMS) issued an alert regarding ecstasy tablets containing para-methoxy-
methamphetamine (PMMA) at high concentration while similar tablets containing MDMA 
were also reported to be circulating.
I 3.3. EMCDDA–Europol Joint reports (Article 5)
In February 2014, after a review of the available information on the new psychoactive 
substance 4,4′-DMAR (see section 3.2), the EMCDDA and Europol launched a formal 
procedure for the collection of information on this substance (9). The Joint Report was 
submitted to the Council, the Commission and the EMA on 8 May 2014 (10).
In April 2014, after a review of the available information on MT-45 (see section 3.2), the 
EMCDDA and Europol launched a formal procedure for the collection of information on 
this substance. The Joint Report was submitted to the Council, the Commission and the 
EMA on 25 June 2014 (11).
I 3.4. Risk assessments (Article 6)
In 2014 the Council of the European Union requested that the Scientific Committee of the 
EMCDDA undertake six risk assessments on new psychoactive substances that have 
emerged in Europe over the past few years and that have been linked to serious harms.
On 29 January 2014 the Council requested that formal risk assessments be conducted on 
four substances: 25I-NBOMe (a substituted phenethylamine with hallucinogenic effects, 
sold as a ‘legal’ alternative to LSD (lysergic acid diethylamide)), AH-7921 (a synthetic 
opioid), MDPV (a synthetic cathinone derivative closely related to pyrovalerone) and 
(9)  The Joint Report Questionnaires were collected by using the new structured collection tool (Excel format).
(10)  EMCDDA–Europol Joint Report on a new psychoactive substance: 4,4′-DMAR (4-methyl-5-(4-methylphenyl)-4,5-
dihydrooxazol-2-amine), July 2014. Available at: www.emcdda.europa.eu/publications/joint-reports/4-4-DMAR 
(11)  EMCDDA–Europol Joint Report on a new psychoactive substance: 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine 
(‘MT-45’), September 2014. Available at: www.emcdda.europa.eu/publications/joint-reports/MT-45
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methoxetamine (an arylcyclohexylamine closely related to ketamine, marketed as its ‘legal’ 
alternative). In accordance with Article 6 of the Council Decision, the risk assessments 
were conducted by the extended Scientific Committee of the EMCDDA on 1 and 2 April 
2014. A Risk Assessment Report for each substance was submitted to the Council and the 
Commission on the 22 April 2014 (12). The four substances were subsequently subjected 
to control measures throughout the European Union as of October 2014.
On the basis of the information provided in the Joint Reports (see section 3.3 above), the 
Council requested that formal risk assessments be conducted on 4,4′-DMAR (on 20 June 
2014) and on MT-45 (25 September 2014). In accordance with Article 6 of the Council 
Decision, a risk assessment for each of the two substances was conducted by the 
extended Scientific Committee of the EMCDDA on 16 September 2014. A Risk 
Assessment Report for each substance was submitted to the Council and the Commission 
on the 19 September 2014 (on 4,4′-DMAR) and on 6 October 2014 (on MT-45).
(12) Risk assessment publications are available at: www.emcdda.europa.eu/publications/risk-assessments 
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I 4. Conclusions
The data presented in this report suggest that the growth of the market in new 
psychoactive substances will continue to pose a range of challenges for public health and 
drug policy over the next few years. Particular challenges relate to the speed at which new 
psychoactive substances appear, their open sale, and, the lack of information on their 
effects and harms. Critically, strong national and regional early warning systems will 
continue to play a central role in the early detection of harms and help to ensure timely 
public health responses within the European Union.
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I  Annex 1New psychoactive substances first notified to the Early Warning System in 2014 under the terms of Council Decision 2005/387/JHA
1.  6-Bromo-MDMA (1-(6-bromo-1,3-benzodioxol-5-yl)-N-methylpropan-2-amine), 
7 January 2014, United Kingdom
2.  2-MeO-diphenidine (1-(1-(2-methoxyphenyl)-2-phenylethyl)piperidine), 14 January 
2014, United Kingdom
3.  Tramadol ((+)-cis-2-[(dimethylamino)methyl]-1-(m-methoxyphenyl)cyclohexanol: 
tramadol), 14 January 2014, United Kingdom
4.  N-methyl-2C-B (4-bromo-N-methyl-2,5-dimethoxyphenethylamine), 15 January 2014, 
Finland
5.  Diphenidine (1-(1,2-diphenylethyl)piperidine), 16 January 2014, Italy, United Kingdom
6.  PB-22 indazole analogue (quinolin-8-yl 1-pentyl-1H-indazole-3-carboxylate), 21 January 
2014, Hungary
7.  5F-PB-22 indazole analogue (quinolin-8-yl 1-(5-fluoropentyl)-1H-indazole-3-
carboxylate), 21 January 2014, Hungary
8.  4-Methyl-N-ethylnorpentedrone (2-(ethylamino)-1-(4-methylphenyl)pentan-1-one), 
28 January 2014, Luxembourg
9.  4F-α-PVP (1-(4-fluorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one), 5 February 2014, 
Sweden
10.  2-APB (1-(1-benzofuran-2-yl)propan-2-amine), 5 February 2014, Sweden
11.  2-MAPB (2-(N-methyl-2-aminopropyl)-1-benzofuran), 5 February 2014, Sweden
12.  3,4-DMeO-α-PVP (1-(3,4-dimethoxyphenyl)-2-(pyrrolidin-1-yl)pentan-1-one), 
7 February 2014, Sweden
13.  4-BEC (1-(4-bromophenyl)-2-(ethylamino)propan-1-one), 10 February 2014, Poland
14.  FDU-PB-22 (1-naphthyl 1-[(4-fluorophenyl)methyl]indole-3-carboxylate), 12 February 
2014, Sweden
15.  JWH-018 indazole analogue (1-naphthalenyl(1-pentyl-1H- indazol-3-yl)-methanone), 
21 February 2014, United Kingdom
16.  3,4-dimethylethcathinone / 3,4-DMEC (1-(3,4-dimethylphenyl)-2-(ethylamino)
propan-1-one), 25 February 2014 , Hungary
17.  Mepirapim ((4-methylpiperazin-1-yl)-(1-pentylindol-3-yl)methanone), 25 February 
2014, Hungary
IMPLEMENTATION REPORTS I EMCDDA–Europol 2014 Annual Report
20 / 27
18.  Quetiapine (2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol), 
28 February 2014, Poland
19.  α-Ethylaminopentiophenone (2-(ethylamino)-1-phenyl-pentan-1-one), 6 March 2014, 
Austria
20.  Eutylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one), 12 March 2014, Poland
21.  Mesembrine ((3aS,7aS)-3a-(3,4-dimethoxyphenyl)-1-methyl-2,3,4,5,7,7a-
hexahydroindol-6-one), 12 March 2014, Austria
22.  α-Pyrrolidinohexanophenone / α-PHP (2-(pyrrolidin-1-yl)-1-(phenyl)hexan-1-one), 
12 March 2014, Poland
23.  4-Fluoro butyrfentanyl (N-(4-fluorophenyl)-N-[(1-(2-phenylethyl)-4-piperidinyl)]
butanamide), 12 March 2014, Poland
24.  Hexedrone (2-(methylamine)-1-(phenyl)hexan-1-one), 12 March 2014, Poland
25.  4’-Chloro-α-PPP (1-(4-chlorophenyl)-2-(1-pyrrolidinyl)propan-1-one), 14 March 2014, 
Poland
26.  2-Methoxyamphetamine (1-(2-methoxyphenyl)propan-2-amine, 24 March 2014 , 
Sweden
27.  4-Fluoro-N-isopropylnorpentedrone (1-(4-fluorophenyl)-2-(1-methylethylamino)
pentan-1-one, 24 March 2014 , Sweden
28.  3-Methoxymethcathinone / 3-MeOMC (1-(3-methoxyphenyl)-2-(methylamino)
propane-1-one, 24 March 2014 , Sweden
29.  Alprazolam triazolobenzophenone derivative ((2-(3-(aminomethyl)-5-methyl-4-H-
1,2,4-triazol-4-yl)-5-chlorophenyl)(phenyl)methanone), 4 April 2014, Spain
30.  AM-2201 benzimidazole analogue / FUBIMINA ((1-(5-fluoropentyl)-1H-benzo[d]
imidazol-2-yl)(naphthalen-1-yl)methanone), 4 April 2014, Latvia and Turkey
31.  4-Bromoamphetamine (1-(4-bromophenyl)propan-2-amine), 7 April 2014, United 
Kingdom
32.  AB-CHMINACA (N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1- (cyclohexylmethyl)-1H-
indazole-3-carboxamide), 10 April 2014, Latvia.
33.  5F-AMBICA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-
carboxamide), 29 April 2014, Sweden
34.  2-Methylmethcathinone (1-(2-methylphenyl)-2-(methylamino)propane-1-one), 8 May 
2014, Sweden
35.  Orphenadrine (N,N-dimethyl-2-(2-methylbenzhydryloxy)ethylamine), 12 May 2014, 
Italy
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36.  DL-4662 (1-(3,4-dimethoxyphenyl)-2-(ethylamino)pentan-1-one), 26 May 2014, 
Sweden
37.  1-(4-fluorophenyl)-2-(piperidin-1-yl)pentan-1-one, 26 May 2014, Sweden
38.  5-MeO-MALT (N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methyl-prop-2-en-1-amine), 
26 May 2014, Sweden
39.  4-Methylpentedrone (1-(4-methylphenyl)-2-methylamino-pentan-1-one), 3 June 2014, 
Czech Republic
40.  5F-AMB (methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl}amino)-3-
methylbutanoate), 18 June 2014, Hungary
41.  JWH-071 ((1-ethyl-1H-indol-3-yl)-1-naphthalenyl-methanone), 19 June 2014, Turkey
42.  NEDPA (N-ethyl-1,2-diphenyl-ethanamine), 19 June 2014, Germany
43.  NPDPA (N-(1,2-diphenylethyl)propan-2-amine), 19 June 2014, Germany
44.  EG-018 (naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone), 20 June 2014, Latvia
45.  Dipentylone (1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-pentan-1-one), 20 June 
2014, Sweden
46.  4-Fluoropentedrone (1-(4-fluorophenyl)-2-(methylamino)pentan-1-one), 24 June 2014, 
France
47.  3-MEC (2-(ethylamino)-1-(3-methylphenyl)propan-1-one), 9 July 2014, Czech Republic 
and Sweden
48.  MN-18 (N-(naphthalen-1-yl)-1-pentyl-1H-indazol-3-carboxamide), 9 July 2014, Sweden
49.  Bupropion (1-((±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone), 9 July 
2014, Slovenia
50.  FUB-AKB48 (N-((3s,5s,7s)-adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
carboxamide, 18 July 2014, Belgium
51.  AB-FUBINACA 2-fluorobenzyl isomer (N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-
[(2-fluorophenyl)methyl]-1H-indazole-3-carboxamide), 4 August 2014, Latvia
52.  Clephedrone (1-(4-chlorophenyl)-2-(methylamino)propan-1-one), 4 August 2014, 
Sweden and Belgium
53.  2-EAPB (1-(1-benzofuran-2-yl)-N-ethylpropan-2-amine), 20 August 2014, Sweden
54.  5-MeO-NiPT (N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-propan-2-amine), 20 August 2014, 
Sweden
55.  4-MeO-α-PBP (1-(4-methoxyphenyl)-2-(pyrrolidin-1-yl)butan-1-one), 20 August 2014, 
Sweden
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56.  Meclonazepam ((S)-5-(2-chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-
benzodiazepin-2-one), 20 August 2014, Sweden
57.  MET (N-methyl-N-ethyltryptamine), 20 August 2014, Norway
58.  NM-2201 (naphthalen-1-yl 1-(5-fluoropentyl)-1H-indol-3-carboxylate), 4 September 
2014, Sweden
59.  Deschloroetizolam, 4 September 2014, United Kingdom
60.  Fentanyl butanamide analogue (N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-
butanamide), 4 September 2014, Poland (Sweden)
61.  5F-SDB-005 (naphthalen-1-yl-1-(5-fluoropentyl)-1H-indazole-3-carboxylate), 
8 September 2014, Romania
62.  W-18 (4-chloro-N-(1-[2-(4-nitrophenyl)ethyl]-piperidin-2-ylidene)benzenesulfonamide), 
10 September 2014, Sweden
63.  α-PBT (2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)butan-1-one), 12 September 2014, Hungary
64.  4F-α-PEP (1-(4-fluorophenyl)-2-(pyrrolidin-1-yl)heptan-1-one), 12 September 2014, 
Hungary
65.  ADB-CHMINACA (N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-
indazole-3-carboxamide), 12 September 2014, Hungary
66.  MDMB-CHMICA (N-[[1-(cyclohexylmethyl)-1H-indol-3-yl]carbonyl]-3-methyl-valine, 
methyl ester), 12 September 2014, Hungary
67.  3F-Phenmetrazine (2-(3-fluorophenyl)-3-methylmorpholine), 18 September 2014, 
Hungary
68.  4-Methyl-N,N-dimethylcathinone (2-dimethylamino-1-(4-methylphenyl)propan-1-one), 
18 September 2014, Spain
69.  EFLEA (N-(1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)propan-2-yl)-N-
methylhydroxylamine), 18 September 2014, Sweden
70.  Acetylfentanyl/desmethylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-
phenylacetamide), 19 September 2014, Poland
71.  3,4-MDPA (α-methyl-N-propyl-1,3-benzodioxole-5-ethanamine), 19 September 2014, 
Poland
72.  α-POP (1-phenyl-2-(pyrrolidin-1-yl)octan-1-one), 22 September 2014, Germany
73.  CUMYL-BICA (1-butyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide), 
23 September 2014, Slovenia
74.  CUMYL-PINACA (1-pentyl-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide), 
23 September 2014, Slovenia
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75.  ADB-CHMICA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-
indole-3-carboxamide), 23 September 2014, Slovenia
76.  CUMYL-5FPICA (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-
carboxamide), 23 September 2014, Slovenia
77.  CUMYL-THPINACA (N-(2-phenylpropan-2-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1-
H-indazole-3-carboxamide), 23 September 2014, Slovenia
78.  CUMYL-PICA (1-pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide), 
23 September 2014, Slovenia
79.  Adrafinil (2-[(diphenylmethyl]sulfinyl]-N-hydroxiacetamide), 26 September 2014, 
Sweden
80.  4F-α-POP (1-(4-fluorophenyl)-2-(pyrrolidin-1-yl)octan-1-one), 9 October 2014, Hungary
81.  DALT (N-allyl-N-[2-(1H-indol-3-yl)ethyl]prop-2-en-1-amine), 13 October 2014, Norway
82.  5-MeO-EIPT (N-ethyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]propan-2-amine), 
13 October 2014, Sweden
83.  CUMYL-5FPINACA (1-(5-fluoropentyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3-
carboxamide), 13 October 2014, Sweden
84.  3-Chloromethcathinone or 3-CMC (1-(3-chlorophenyl)-2-(methylamino)propan-1-one, 
14 October 2014, Sweden
85.  5-APB NBOMe (1-(benzofuran-5-yl)-N-[(2-methoxyphenyl)methyl]propan-2-amine), 
17 October 2014, Germany
86.  4-MMA NBOMe (N-[(2-methoxyphenyl)methyl]-N-methyl-1-(p-tolyl)propan-2-amine), 
17 October 2014, Germany
87.  4-EA NBOMe (1-(4-ethylphenyl)-N-[(2-methoxyphenyl)methyl]propan-2-amine), 
17 October 2014, Germany
88.  3,4-DMA NBOMe (1-(3,4-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]propan-2-
amine), 17 October 2014, Germany
89.  4-Methyl-N,N-diethylcathinone (2-diethylamino-1-(4-methylphenyl)propan-1-one), 
20 October 2014, France
90.  Afloqualone (6-amino-2-(fluoromethyl)-3-(2-methylphenyl)-3H-quinazolin-4-one), 
20 October 2014, Sweden
91.  Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo-[4,3a][1,4]
benzodiazepine), 20 October 2014, Sweden
92.  Modafiendz (2-{[bis(4-fluorophenyl)methyl]sulfinyl}-N-methylacetamide (N-methyl-
4,4-difluoro-modafinil)), 23 October 2014, Luxembourg.
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93.  Methylmethaqualone (3-(2,4-dimethylphenyl)-2-methylquinazolin-4(3H)-one), 
28 October 2014, Poland
94.  5F-APP-PINACA (N-(2-amino-1-benzyl-2-oxo-ethyl)-1-(5-fluoropentyl)indazole-3-
carboxamide), 6 November 2014, Sweden
95.  APP-FUBINACA (N-(2-amino-1-benzyl-2-oxo-ethyl)-1-[(4-fluorophenyl)methyl]
indazole-3-carboxamide), 6 November 2014, Sweden
96.  MDPHP (1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-yl-hexan-1-one), 6 November 2014, 
Sweden
97.  4-MeO-α-PEP (1-(4-methoxyphenyl)-2-pyrrolidin-1-yl-heptan-1-one), 19 November 
2014, France
98.  5F-APP-PICA (N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-
carboxamide), 25 November 2014, Sweden
99.  5F-AMB-PICA (methyl (1-(5-fluoropentyl)-1H-indole-3-carbonyl)-L-valinate), 
5 December 2014, Hungary.
100.  Flibanserin (1-(2-(4-[3-(trifluormethyl)phenyl]piperazine-1-yl)ethyl)-1,3-dihydro-2H-
benzimidazole-2-one), 05 December 2014, Germany.
101.  AMB-FUBINACA (methyl-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)-3-
methylbutanoate), 10 December 2014, Sweden
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I  Annex 2New psychoactive substances in Europe. An update from the EU Early Warning System (March 2015)
An update from the EU Early Warning System 
March 2015
New psychoactive 
substances in Europe
Available at: www.emcdda.europa.eu/publications/2015/new-psychoactive-substances
IMPLEMENTATION REPORTS I EMCDDA–Europol 2014 Annual Report
26 / 27
I  Annex 3Infographic: New psychoactive substances in Europe. An update from the EU Early Warning System (March 2015)
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Since 1997, the EMCDDA has played a central role in 
Europe's response to new psychoactive substances.  
Its main responsibilities in this eld are to operate the 
EU Early Warning System, with its partner Europol, and 
to undertake risk assessments of new substances 
when necessary. e EU Early Warning System works 
by collecting information on the appearance of new 
substances from the 28 EU Member States, Turkey 
and Norway, and then monitoring them for signals of 
harm, allowing the EU to respond rapidly to emerging 
threats. 
Synthetic cannabinoids (left panel) and synthetic 
cathinones (right) make up the largest groups of new 
psychoactive substances monitored by the EMCDDA 
and, respectively, reect the demand for cannabis and 
stimulants in Europe. However, the EMCDDA also 
monitors many new substances that come from a 
range of other groups, including phenethylamines, 
opioids, tryptamines, benzodiazepines, 
arylalkylamines and piperazines. All these substances 
require monitoring in order to identify signals of serious 
harms as early as possible. Opioids, for example, are of 
special concern for public health because they pose a 
very high risk of overdose and death. During 2014, 
serious harms that required urgent attention led to    
16 public health alerts being issued by the EMCDDA, 
while 6 new substances — 25I-NBOMe, AH-7921, 
methoxetamine, MDPV, 4,4′-DMAR and MT-45 — 
required risk assessment by the EMCDDA's Scientic 
Committee.
Read the full report at
emcdda.europa.eu/publications/2015/new-psychoactive-substances
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New psychoactive substances in Europe
e market 
Legal highs
Marketed in bright and attractive 
packaging. Sold openly in head/smart 
shops and online. Aimed at recreational 
users.
Research chemicals
Sold under the guise of being used for 
scientic research. Aimed at 
'psychonauts' who explore the e¥ects of 
psychoactive substances. Sold openly 
online.
Food supplements
Sold under the guise of being food or 
dietary supplements. Aimed at people 
wanting to enhance their body and mind. 
Sold openly in tness shops and online.
Designer drugs
Passed o¥ as drugs such as MDMA and 
heroin. Produced in clandestine labs by 
organised crime. Sold on illicit drug 
market by drug dealers. 
Medicines
Medicines that are diverted from patients 
or illegally imported into Europe. Sold on 
illicit drug market by drug dealers.    
New psychoactive substances (NPS) — at a glance
From synthesis to consumer
Chemical companies based in China and 
India synthesise NPS in bulk quantity 
Shipped by air or sea to Europe  Processed and packaged into legal highs, research 
chemicals and food supplements
Sold openly in head/smart 
shops and online 
8 % of young adults have 
used NPS in their life 
(Eurobarometer)
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